The advent of immunotherapy, specifically of immune checkpoint inhibitors (ICIs), for the
treatment of solid tumors has deeply transformed therapeutic algorithms in medical …

Immunotherapy with immune checkpoint inhibitors (ICIs) nowadays has indications for
several solid tumors. The current targets for ICIs are CTLA-4, PD-1, and PD-L1 receptors …

Abstract Background and Aims The association between cancer treatments and
exacerbation of inflammatory bowel diseases [IBD] is unclear. We aimed to evaluate the …

Simple Summary Liver cancer continues to exhibit increasing incidence and mortality
worldwide. Subsequently, there has been a concomitant effort to development novel …

Simple Summary Physicians face therapeutic choices in an increasing number of IBD
patients with current or past malignancy. Even if uncontrolled IBD may lead to severe …

Summary Background Immune checkpoint inhibitors (ICIs) are effective oncologic agents
which frequently cause immune‐related adverse events (irAEs) which can impact multiple …

Background Inflammatory bowel disease (IBD; mainly ulcerative colitis and Crohn's disease)
is associated with the development of colorectal cancer (CRC) referred to as colitis …

Introduction Prescribing immune checkpoint inhibitors (ICIs) to cancer patients with an
autoimmune disease (AID) is presumed safe when cautious adverse event management is …

▼ Résumé L'immunothérapie des cancers est en plein développement. Les inhibiteurs de
point de contrôle immunitaire (ICI), c'est-à-dire les anticorps anti-CTLA4 et anti-PD1, sont à …

English Immunotherapy in cancer is coming of age. Immune checkpoint inhibitors (ICI),
namely anti-CTLA4 and anti-PD1 antibodies, can lead to immune-related adverse events …